Skip to main
RARE
RARE logo

Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

Ultragenyx Pharmaceutical (RARE) Analyst Ratings

Based on 30 analyst ratings
Buy
Strong Buy 37%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 3%

Bulls say

Ultragenyx Pharmaceutical Inc. is poised for growth, particularly with its lead product, Crysvita, generating over $1 billion in annual worldwide end-user revenue and expanding its market presence in Latin America and Turkey. The company's advancements in therapeutic developments, including UX111, have shown significant cognitive and functional improvements in patients compared to untreated ones, which could drive further commercial success. Additionally, the anticipated approval of UX111 is expected to contribute to achieving GAAP profitability by 2027, reinforcing the company's solid foundation and potential for value creation in the rare disease market.

Bears say

Ultragenyx Pharmaceutical Inc. faces a negatively skewed outlook due to several fundamental concerns impacting its financial stability. Key risks include lower-than-expected revenues from its core products, Crysvita and Dojolvi, alongside mounting competition, particularly from advancements in gene therapy that could challenge the efficacy of its drugs. Moreover, the company is vulnerable to clinical trial risks, regulatory hurdles, and uncertainties regarding commercial opportunities, all of which could significantly affect future sales estimates and operational funding.

Ultragenyx Pharmaceutical (RARE) has been analyzed by 30 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ultragenyx Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ultragenyx Pharmaceutical (RARE) Forecast

Analysts have given Ultragenyx Pharmaceutical (RARE) a Buy based on their latest research and market trends.

According to 30 analysts, Ultragenyx Pharmaceutical (RARE) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $84.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $84.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ultragenyx Pharmaceutical (RARE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.